We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




World’s First One-Minute Hepatitis C Antibody Test Facilitates Quick Triage

By LabMedica International staff writers
Posted on 21 May 2024
Print article
Image: The INSTI HCV Antibody Test is the world’s first one minute test (Photo courtesy of bioLytical Laboratories)
Image: The INSTI HCV Antibody Test is the world’s first one minute test (Photo courtesy of bioLytical Laboratories)

Rapid and accurate testing is crucial in the fight against Hepatitis C. Having regular access to testing helps ensure the prompt identification of potential Hepatitis C infections and facilitates immediate linkage to care, thus helping to reduce further transmission. Now, the first one-minute Hepatitis C antibody test can prove to be an excellent tool in managing this disease.

The INSTI HCV Antibody Test from bioLytical Laboratories (Richmond, BC, Canada) is the world’s first one-minute test that detects antibodies to the Hepatitis C virus, which are substances released into the bloodstream upon infection. The test includes procedural control for IgG and IgM and can identify HCV genotypes 1 through 6, delivering results in as little as 60 seconds. It is both highly accurate and affordable, designed for ease of use. This fully portable system does not require any additional equipment, enabling healthcare providers to conduct tests in various settings, from clinical laboratories to remote testing locations.

By providing results in one minute or less, the INSTI HCV Antibody Test supports rapid triage and facilitates quick access to treatment. Its quick turnaround is ideal for integration into diverse healthcare workflows. The test is simple to administer via a simple finger prick and requires minimal training, making it adaptable to a variety of settings, including clinics and emergency environments. By eliminating the need for venepuncture, the INSTI HCV Antibody Test reduces delays in treatment and improves the connection to subsequent care and treatment, meeting a critical clinical need.

“Our INSTI HCV Antibody Test provides a rapid and reliable tool to identify hepatitis C cases quickly, helping healthcare professionals test high-risk populations and reduce transmission,” said Robert Mackie, bioLytical CEO.

Related Links:
bioLytical Laboratories


Print article

Channels

Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Industry

view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.